SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending due to rapidly escalating geopolitical tensions in the Middle East following reports of U.S.-Israeli strikes on Iran and subsequent retaliatory actions, with the community actively debating whether crude oil prices will surge higher on potential Strait of Hormuz disruptions or if the rally will prove temporary despite a significant military buildup in the region.

SSgA Active Trust - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

XLE is trending due to U.S. intervention in Venezuela and escalating geopolitical tensions in the Middle East, particularly around the Strait of Hormuz, which is fueling a significant "war risk premium" in oil prices and leading the community to anticipate massive upside for energy stocks.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd (INDO) is trending as escalating Middle East geopolitical tensions, including concerns over oil supply chokepoints like the Strait of Hormuz, are fueling community anticipation of surging crude prices and a potential short squeeze for this low-float energy stock.

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

UroGen Pharma Ltd

UroGen Pharma is trending as its recently FDA-approved ZUSDURI, a potential bladder cancer "game-changer," prepares for commercial launch, driving community optimism about significant revenue growth and a possible buyout, despite some stock volatility.

Fan Tokens allow fans across multiple sports verticals to exercise their share of influence within their favourite teams/leagues/clubs. Through Socios.com, fans are empowered to participate in certain club decisions, for example, choosing a goal celebration song in a football stadium, choosing which fighters should go head to head in MMA, and more. Thanks to Fan Tokens, holders receive access to once-in-a-lifetime experiences such as player meet and greets, training day events &amp; much much more.  The growing list of partnerships launching their Fan Tokens on the Socios.com platform includes some of the biggest sporting organizations in the world such as FC Barcelona, Inter Milan, AC Milan, Manchester City, UFC, ROUSH Fenway Racing, Aston Martin, just to name a few.

Italian National Football Team Fan Token

ITA is trending amidst escalating global geopolitical tensions, particularly from conflicts in the Middle East, driving investor discussion around defense stocks. The community is actively debating the sector's resilience and its role as a potential hedge, even as some traders take profits after recent rallies.

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product NexoBrid, is an orphan biologic for eschar removal in severe burns. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.

MediWound Ltd

MediWound is trending as investors eagerly anticipate a potential BARDA contract for its burn treatment NexoBrid, which recently showed strong efficacy in blast injuries, alongside promising advancements for its EscharEx chronic wound therapy. This momentum, including institutional interest and buyout speculation, is driving conversation despite polarized views on the stock's ability to break through current trading ranges.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is trending amid enthusiasm for positive Phase 3 clinical trial results for its HER2-positive breast cancer drug and encouraging lung cancer therapy data, fueling community discussions about its oncology pipeline and strategic pivot, even as some debate recent analyst upgrades against news of a partner offloading its stake.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevron is trending as intensifying geopolitical tensions in the Middle East, particularly regarding potential oil supply disruptions and the Strait of Hormuz, are driving crude prices higher. The community is actively discussing Chevron's strategic advantages, including expanded access to Venezuelan oil and new global exploration deals, positioning it for potential gains amid these market shifts.

SSgA Active Trust - State Street SPDR Dow Jones Industrial Average ETF Trust

DIA is trending amidst escalating US-Iran geopolitical tensions, characterized by reports of military actions and leadership changes, coupled with market uncertainty following the Supreme Court's tariff ruling and subsequent threats of new tariffs from President Trump. The community is sharply divided between anticipating a potential market rally and fearing a significant downturn due to these events and broader economic concerns.

Lockheed Martin Corp. is a global security and aerospace company, which engages in the research, design, development, manufacture, integration, and sustainment of technology systems, products, and services. It operates through the following business segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems (RMS), and Space. The Aeronautics segment researches, designs, develops, manufactures, integrates, sustains, supports, and upgrades advanced military aircraft, including combat and air mobility aircraft, unmanned air vehicles, and related technologies. The MFC segment is involved in air and missile defense systems, tactical missiles and air-to-ground precision strike weapon systems, logistics, fire control systems, mission operations support, readiness, engineering support and integration services, manned and unmanned ground vehicles, and energy management solutions. The RMS segment designs, manufactures, services, and supports various military and commercial helicopters, surface ships, sea and land-based missile defense systems, radar systems, sea and air-based mission and combat systems, command and control mission solutions, cyber solutions, and simulation and training solutions. The Space segment includes the production of satellites, space transportation systems, and strategic, advanced strike, and defensive systems. The company was founded in 1995 and is headquartered in Bethesda, MD.

Lockheed Martin Corp.

Lockheed Martin is actively discussed as a prime beneficiary of escalating Middle East tensions, with the community anticipating increased defense spending and military action. Conversation centers on its robust order backlog and recent technical breakout, while some note its potentially overbought market positioning.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Evolent Health (NYSE:EVH) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded Evolent Health from a "sell" rating to a "hold" rating in a research report on Saturday...

Evolent to Participate in Upcoming Investor Conferences

Evolent to Participate in Upcoming Investor Conferences Evolent to Participate in Upcoming Investor Conferences PR Newswire WASHINGTON, Feb. 26, 2026 WASHINGTON, Feb. 26, 2026 /PRNewswire/ -- Evolent...

Evolent Health (NYSE:EVH) Price Target Lowered to $4.00 at Citigroup

Citigroup lowered their price objective on shares of Evolent Health from $6.00 to $4.00 and set a "buy" rating on the stock in a research report on Thursday...

UBS Group Lowers Evolent Health (NYSE:EVH) Price Target to $5.00

UBS Group reduced their price objective on shares of Evolent Health from $10.00 to $5.00 and set a "buy" rating for the company in a research report on Thursday...

Evolent Health (NYSE:EVH) Price Target Lowered to $4.00 at Needham & Company LLC

Needham & Company LLC lowered their price target on shares of Evolent Health from $15.00 to $4.00 and set a "buy" rating on the stock in a report on Wednesday...

Royal Bank Of Canada Cuts Evolent Health (NYSE:EVH) Price Target to $3.00

Royal Bank Of Canada reduced their target price on shares of Evolent Health from $5.00 to $3.00 and set a "sector perform" rating for the company in a research report on Wednesday...

KeyCorp Downgrades Evolent Health (NYSE:EVH) to Sector Weight

KeyCorp lowered shares of Evolent Health from an "overweight" rating to a "sector weight" rating in a report on Wednesday...

BTIG Research Issues Pessimistic Forecast for Evolent Health (NYSE:EVH) Stock Price

BTIG Research cut their price objective on Evolent Health from $10.00 to $8.00 and set a "buy" rating for the company in a research report on Wednesday...

Evolent Health Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

<ul class="summary-bullets"><li>The company’s EBITDA forecast of around $110 million to $140 million falls short of its FY2025 EBITDA of $151.2 million.</li><li>Evolent’s Q4 revenue fell 27% to $468.7 million, but beat estimates of $467.5 million, according to Fiscal.ai data.</li><li>Keybanc sees Evolent’s debt leverage rising to about seven times before potentially moderating.</li></ul>Shares of Evolent Health (EVH) fell more than 5% in pre-market trading on Wednesday, following a bearish brokerage action after the company announced lower earnings guidance alongside its fourth-quarter results.If the pre-market levels hold after the opening bell, <a href="https://stocktwits.com/symbol/EVH">EVH stock</a> would fall to an all-time low. This adds to the heavy selling pressure over the past month, during which the shares have slumped 31%.The company also generated significant retail buzz. According to Stocktwits data, message volume on the platform increased by 1,850% over the past 24 hours and by 1,200% over the past seven days.<h2 class="st-heading-2">Q4 Revenue Beats Estimates Despite 27% Drop</h2>Evolent’s fourth-quarter revenue declined 27% to $468.7 million, but came in just over Wall Street’s estimates of $467.5 million, according to Fiscal.ai data. On an adjusted basis, the company reported earnings of $0.08 per share, beating consensus estimates of $0.05 per share.Evolent forecasts full-year 2026 revenue to be in the range of $2.4 billion to $2.6 billion, above the $1.88 billion revenue it reported in FY 2025. However, its adjusted earnings before interest, tax, depreciation and amortization (EBITDA) forecast of around $110 million to $140 million falls short of its FY2025 EBITDA of $151.2 million.“While the addition of $900 million in new Performance Suite revenue in 2026, as well as the impact of significant health plan customer membership decreases in their Exchange products, create an impact on Adjusted EBITDA in the first half of the year, we believe our year-end 2026 margins should quickly step-up as new contract reserving effects ease throughout the year and our operating cost reduction plan ramps up across 2026,” CEO Seth Blackley said.<h2 class="st-heading-2">Keybanc Flags Lack Of Visibility In EBITDA Recovery&nbsp;</h2>KeyBanc downgraded Evolent Health to ‘Sector Weight’ from ‘Overweight’ without adding a price target, according to The Fly. Although the firm described Evolent’s Q4 results as ‘solid’, KeyBanc had expected the company’s debt leverage to begin easing in early 2026. Instead, the brokerage sees leverage rising to about seven times before potentially moderating later in 2026.Keybanc also added that the downgrade reflects “limited visibility into a meaningful EBITDA recovery in the near term.”“While this increase in revenue creates a powerful foundation for EBITDA acceleration, it also creates a temporary headwind in 2026 due to our reserving methodologies and the timing of implementation of the new contracts. Second, Specialty TNS 2026 performance is experiencing a significant headwind from exchange membership declines consistent with the entire industry,” CFO Mario Ramos said in a call with analysts.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the pre-market fall, retail sentiment turned ‘neutral’ from ‘bearish’ a day earlier, amid ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/EVH_jpg_11849304d8.webp" alt="EVH.jpg">One user said the stock’s decline doesn’t reflect its fair value.<stembedurl>https://stocktwits.com/BPler/message/645782444</stembedurl>Another user does not expect the stock price to drop any further.<stembedurl>https://stocktwits.com/PHILMYWALLET/message/645787843</stembedurl>The stock has been in an extended downtrend, declining more than 34% so far in 2026 and over 75% in the past year.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/nasdaq-sp500-futures-subdued-nvda-nflx-wbd-unh-lcid-wulf-stocks-to-watch/cZRUzKuR46j">Nasdaq, S&amp;P 500 Futures Subdued Ahead Of Nvidia Earnings: Why WBD, NFLX, UNH, LCID, WULF Are On Traders' Radar Today</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Evolent Health logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

EVH Stock On Track To Open At Record Low – Here’s Why Keybanc Turned Cautious 

KeyBanc downgraded Evolent Health to ‘Sector Weight’ from ‘Overweight’, citing a lack of visibility in near-term EBITDA recovery.

Equity

Evolent Health, Inc. engages in the provision of healthcare delivery and payment services. It deals with population health management, health plan and third party administration, network performance and pharmacy benefit management, risk adjustment, analytics and performance improvement, and technology and electronic medical record integration. The firm operates through Services and True Health segments. The Services segment includes clinical and administrative solutions such as total cost of care management and specialty care management and comprehensive health plan administrative services. The True Health segment offers a physician-led health plan for employer-sponsored health coverage. The company was founded by Frank J. Williams, Seth B. Blackley, and Thomas Peterson III in August 2011 and is headquartered in Arlington, VA.

Evolent Health Inc - Ordinary Shares - Class A

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.04	--	--	N/A
Q4 '25	$0.05	$0.08	56.56%	BEAT
Q3 '25	$0.10	$0.05	-51.18%	MISSED
Q2 '25	$0.07	-$0.10	-234.79%	MISSED
Q1 '25	$0.09	$0.06	-36.11%	MISSED

EVH
Evolent Health Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest EVH News

EVHEvolent Health Inc - Ordinary Shares - Class A